Prosecution Insights
Last updated: November 20, 2026
Application No. 18/682,716

METHODS FOR SIMULTANEOUS MUTATION DETECTION AND METHYLATION ANALYSIS

Non-Final OA §112
Filed
Feb 09, 2024
Priority
Aug 12, 2021 — provisional 63/232,438 +2 more
Examiner
HANEY, AMANDA MARIE
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Johns Hopkins University
OA Round
1 (Non-Final)
36%
Grant Probability
At Risk
1-2
OA Rounds
8m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants only 36% of cases
36%
Career Allowance Rate
266 granted / 728 resolved
-23.5% vs TC avg
Strong +45% interview lift
Without
With
+45.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
53 currently pending
Career history
792
Total Applications
across all art units

Statute-Specific Performance

§101
23.3%
-16.7% vs TC avg
§103
23.3%
-16.7% vs TC avg
§102
10.3%
-29.7% vs TC avg
§112
32.7%
-7.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 728 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. Applicant’s election without traverse of (i) substitution as the species of genetic characteristic and (ii) methylation as the species of epigenetic characteristic in the reply filed on July 24, 2026 is acknowledged. Claims 1-2, 4-6, 8, 10-11, 13, 19-21, 24-26, 28, 30, 34, 37, and 43 are currently pending and have been examined herein. Claim Rejections - 35 USC § 112(b) 3. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-2, 4-6, 8, 10-11, 13, 19-21, 24-26, 28, 30, 34, 37, and 43 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1-2, 4-6, 8, 10-11, 13, 19 are rejected over the recitation of the phrase “the reverse complement” in claim 1 step (a). There is insufficient antecedent basis for this limitation in the claim. Claims 1-2, 4-6, 8, 10-11, 13, 19 are drawn to a method of assaying at least one strand of a double stranded DNA molecule (preamble). The recitation of “at least one strand” is confusing because the claims actually appear to require assaying both strands. For example they require adding adapters to both the Watson and Crick strands, they require copying both strands, etc. Clarification is required. Claims 1-2, 4-6, 8, 10-11, 13, 19 are rejected over the recitation of the phrase “the amplified products” in claim 1 step (c). There is insufficient antecedent basis for this limitation in the claim. Claims 1-2, 4-6, 8, 10-11, 13, 19 are rejected over the recitation of “separately recovering the adapted Watson and Crick strands and the tagged Watson and Crick strands”. This recitation is confusing because the claims previously required attaching adapters to a double stranded DNA molecule and then a round of linear amplification of the adapted double stranded DNA with a tagged primer. It thus appears that the resulting strands are all adapted and tagged. Therefore it is unclear how one could go about separating the adapted strands and the tagged strands. Clarification is required. Claims 1-2, 4-6, 8, 10-11, 13, 19 recite “generating a first sequencing read” (step (e)) and “generating a second sequencing read” (step (f)). Here “read” is used in singular form. The claims then recite “grouping the first sequencing reads” (step (g)) and “grouping the second sequencing reads” (step (h)). Hear “reads” is plural. Thus it is unclear if the claims require a single sequence read or if multiple reads are obtained. Claims 1-2, 4-6, 8, 10-11, 13, 19 are as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: those that allow one to identify a epigenetic characteristic. The claims require sequencing DNA. However, they do not set forth the steps that would be required to identify a epigenetic characteristic based on the obtained DNA sequence. The claims encompass epigenetic characteristics such as methylation, hydroxy methylation, histone modification, microRNA regulation, acetylation, phosphorylation, ubiquitination, or sumoylation but do not set forth how the sequencing data is analyzed/manipulated to identify these characteristics. Claims 20, 21, 24-26, 28, 30, 34, 37, and 43 are rejected over the recitation of the phrase “the reverse complement” in claim 20 step (a). There is insufficient antecedent basis for this limitation in the claim. Claims 20, 21, 24-26, 28, 30, 34, 37, and 43 are drawn to a method of assaying at least one strand of a double stranded DNA molecule (preamble). The recitation of “at least one strand” is confusing because the claims actually appear to require assaying both strands. For example they require adding adapters to both the Watson and Crick strands, they require copying both strands, etc. Clarification is required. Claims 20, 21, 24-26, 28, 30, 34, 37, and 43 are rejected over the recitation of the phrase “the amplified products” in claim 1 step (c). There is insufficient antecedent basis for this limitation in the claim. Claims 20, 21, 24-26, 28, 30, 34, 37, and 43 are rejected over the recitation of “separately recovering the adapted Watson and Crick strands and the tagged Watson and Crick strands”. This recitation is confusing because the claims previously required attaching adapters to a double stranded DNA molecule and then a round of linear amplification of the adapted double stranded DNA with a tagged primer. It thus appears that the resulting strands are all adapted and tagged. Therefore it is unclear how one could go about separating the adapted strands and the tagged strands. Clarification is required. Claims 20, 21, 24-26, 28, 30, 34, 37, and 43 recite “generating a first sequencing read” (step (e)) and “generating a second sequencing read” (step (f)). Here “read” is used in singular form. The claims then recite “grouping the first sequencing reads” (step (g)) and “grouping the second sequencing reads” (step (h)). Hear “reads” is plural. Thus it is unclear if the claims require a single sequence read or if multiple reads are obtained. Claims 30, 34, and 37 are as being incomplete for omitting essential steps, such omission amounting to a gap between the steps. See MPEP § 2172.01. The omitted steps are: those that allow one to identify a epigenetic characteristic. The claims require sequencing DNA. However, they do not set forth the steps that would be required identify a epigenetic characteristic based on the obtained DNA sequence. The claims encompass epigenetic characteristics such as methylation, hydroxy methylation, histone modification, microRNA regulation, acetylation, phosphorylation, ubiquitination, or sumoylation but do not set forth how the sequencing data is analyzed/manipulated to identify these characteristics. Claim Rejections - 35 USC § 112(d) 4. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 19 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 19 is drawn to a method that identifies a genetic characteristic and an epigenetic characteristic of a double-stranded DNA molecule in a population of double-stranded DNA molecules by assaying both strands of the double-stranded DNA molecule. The claims fails to further limit the method of claim 1 because these limitations are already required by claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim 43 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 43 is drawn to a method that identifies a first characteristic and a second characteristic of a double stranded DNA molecule in a population of double-stranded DNA molecules by assaying both strands of the double-stranded DNA molecule. The claims fails to further limit the method of claim 20 because these limitations are already required by claim 20. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 112 5. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-2, 4-6, 8, 10-11, 13, 19-21, 24-26, 28, 30, 34, 37, and 43 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of identifying a genetic characteristic and a methylation characteristic of a double stranded DNA molecule, does not reasonably provide enablement for a method of identifying a genetic characteristic and ANY type of epigenetic characteristic of a double stranded DNA molecule. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. Claims 1-2, 4-6, 8, 10-11, 13, and 19 are drawn to a method of identifying a genetic characteristic and an epigenetic characteristic of a double-stranded DNA molecule in a population of double-stranded DNA molecules by assaying at least one strand of the double-stranded DNA molecule. In view of the recitation of “epigenetic characteristic” the claims broadly encompass detection of ANY type of epigenetic characteristic. Only claim 13 is limited to specific types of epigenetic characteristics, namely, methylation, hydroxy methylation, histone modification, microRNA regulation, acetylation, phosphorylation, ubiquitination, or sumoylation. Claims 19-21, 24-26, 28, 30, 34, 37, and 43 are drawn to a method of identifying a first characteristic and a second characteristic of a double stranded DNA molecule in a population of double-stranded DNA molecules by assaying at least one strand of the double-stranded DNA molecule. Claim 30 states that the first characteristic is a genetic characteristic or an epigenetic characteristic, and the second characteristic is a genetic characteristic or an epigenetic characteristic. In view of the recitation of “epigenetic characteristic” the claims broadly encompass detection of ANY type of epigenetic characteristic. Only claim 37 is limited to specific types of epigenetic characteristics, namely, methylation, hydroxy methylation, histone modification, microRNA regulation, acetylation, phosphorylation, ubiquitination, or sumoylation. The nature of the invention requires being able to identify ANY epigenetic characteristic and particularly those specifically recited in claims 13 and 37 by nucleic acid sequencing. The specification (para 0192) teaches that the term “epigenetic characteristic” can refer to a heritable phenotype change that does not involve a change in DNA sequence. In some embodiments, an epigenetic characteristic includes a functionally relevant changes to the genome that does not involve a change in the nucleotide sequence. In some embodiments, the epigenetic characteristic is hydroxy methylation, histone modification, microRNA regulation, acetylation, phosphorylation, ubiquitination, or sumoylation. In some embodiments, the epigenetic characteristic is methylation. In some embodiments, the epigenetic characteristic is a differentially methylated regions (DMR). In some embodiments, the epigenetic characteristic is a methylation pattern. The specification (para 0193) teaches that the methods described herein can be used to detect methylation at a CpG dinucleotide in one or both strands of a double strand DNA molecule (e.g., both strands simultaneously). In some embodiments, a population of DNA molecules is treated with bisulfite to convert Cytosine bases in the DNA molecules to Uracil bases, forming a population of converted DNA molecules. In some embodiments, molecular barcodes are attached to both strands of the population of converted DNA molecules using an excess of target-specific amplification primers attached to molecular barcodes, forming a population of amplified, barcoded, converted DNA molecules. In some embodiments, the amplified, barcoded, converted DNA molecules are amplified in an amplification reaction to form families of amplified, barcoded, converted DNA molecules, wherein amplified, barcoded, converted DNA molecules that share the same molecular barcode form a family of DNA molecules. In some embodiments, a plurality of members of the families is subjected to sequencing reactions to obtain nucleotide sequences of both strands of said plurality of members of the families. In some embodiments, nucleotide sequences of a plurality of members of a family are compared and families in which >90% of the members contain a selected methylated C at a CpG dinucleotide are identified. In some embodiments, nucleotide sequences of two complementary strands of an amplified, barcoded, converted DNA molecule are compared and a methylated C at the CpG dinucleotide is identified in two complementary strands. The specification further exemplifies bisulfite treatment, library preparation, and sequencing to detect methylation (Examples 1, 2, 3). While methods of sequencing to detect the epigenetic characteristic of methylation are described in the specification, methods of sequencing to detect the epigenetic characteristics of hydroxy methylation, histone modification, microRNA regulation, acetylation, phosphorylation, ubiquitination, and sumoylation are NOT described in the specification. The instant claims require sequencing which allows one to detect changes in a nucleic acid sequence. However, several of the recited epigenetic characteristics do not involve a change in DNA sequence (para 0192). For example histone modification, acetylation, phosphorylation, ubiquitination, and sumoylation are protein modifications that conventional nucleic acid sequencing methods do not detect. There is no guidance in the specification on how sequencing data can be to identify these types of protein modifications. The specification does not provide enablement for a method that encompasses nucleic acid sequencing to detect protein modifications. Additionally microRNA regulation is not something that conventional nucleic acid sequencing methods can detect. While sequencing can detect/quantify miRNAs and expression, detection of “regulation” would require additional methods steps that are not described in the specification. The specification does not provide enablement for a method that encompasses nucleic acid sequencing to detect microRNA regulation. Further it is noted that there is no guidance in the specification on how to detect hydroxy methylation. While the specification discloses the use of bisulfite treatment which allows the detection of methylation by converting unmethylated cytosine into uracil, detection of hydroxy methylation would require additional methods steps that are not described in the specification. The specification does not provide enablement for a method that encompasses nucleic acid sequencing to detect hydroxy methylation. For the reasons discussed above, it would have required undue and unpredictableexperimentation to practice the recited methods in the full broad scope encompassed by the rejected claims. Herein, although the level of skill in the art is high, given the lack of disclosure in the specification and the unpredictability of the art, it would require undue experimentation for one of skill in the art to make and use the invention as broadly claimed. Relevant Prior Art 6. The closest prior art is Eltoukhy (US 2016/0046986 Pub 2/18/2016). Eltoukhy teaches a method for determining genetic variants in a polynucleotide sample, wherein the genetic variant can be a base change, insertion, repeat, deletion, copy number variation, epigenetic modification (abstract, para 0225). Eltoukhy teaches tagging both halves of a double stranded molecule such that each original Watson and Crick strand is differentially tagged (para 0006). Eltoukhy teaches that the tags can be adapters, wherein the adapters can comprise molecular barcodes, a primer sequence, and an adapter sequence (para 0008, 0017). Eltoukhy teaches that the adapters are added to both ends of the double stranded molecules (para 0019). Eltoukhy teaches performing high fidelity amplification on the tagged DNA fragments (para 0019). Eltoukhy teaches that the high fidelity amplification can be PCR which comprises cycles of denaturation, annealing, and synthesis (para 0155). Eltoukhy teaches sequencing both strands of the tagged and amplified DNA to obtain sequence reads comprising nucleotide sequences of the molecular barcodes and at least a portion of the original DNA fragments (para 0019). Eltoukhy teaches binning the sequence reads according to the molecular barcodes to create bins of single stranded reads (para 0023). Eltoukhy teaches analyzing the nucleic acid sequences to identify one or more genetic variants (para 0027). However Eltoukhy does not teach the following limitations: (a) a method wherein the molecular barcode of the adapted Watson strand is the reverse complement of the molecular barcode of the adapted Crick strand, (b) copying comprises (i) contacting the adapted double-stranded DNA molecule with a tagged primer and (ii) performing a round of linear extension of the adapted double- stranded DNA molecule, generating a tagged Watson strand and a tagged Crick strand; and (c) separately recovering the adapted Watson and Crick strands and the tagged Watson and Crick strands. The prior art does not provide any teachings, suggestions, or motivations that would have led a person of ordinary skill in the art to modify the method of Eltoukhy to incorporate these missing limitations. Thus the prior art does not teach or suggested the claimed method as a whole. 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMANDA HANEY whose telephone number is (571)272-8668. The examiner can normally be reached Monday-Friday, 8:15am-4:45pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu-Cheng Shen can be reached at 571-272-3157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMANDA HANEY/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Feb 09, 2024
Application Filed
Oct 02, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799529
MASSIVELY PARALLEL SEQUENCING USING UNLABELED NUCLEOTIDES
5y 6m to grant Granted Nov 17, 2026
Patent 12790646
METHODS FOR DETECTING, MONITORING, AND GUIDING TREATMENT OF ALLOGRAFT REJECTION USING DISCRIMINATING GENE EXPRESSION SIGNATURES
4y 6m to grant Granted Nov 10, 2026
Patent 12760357
SYSTEM AND METHOD FOR TISSUE-WIDE SINGLE CELL POST-TRANSCRIPTIONAL PROFILING OF MULTIPLE MOLECULAR TARGETS
4y 1m to grant Granted Oct 13, 2026
Patent 12747478
COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS AND PROGNOSIS
5y 1m to grant Granted Sep 29, 2026
Patent 12735745
FUS/TLS-BASED COMPOUNDS AND METHODS FOR DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED MOTOR NEURON DISEASES
5y 3m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
36%
Grant Probability
82%
With Interview (+45.1%)
3y 6m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 728 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month